Morning Trend | NUOBIKAN sees increased volume and stops falling, sparking interest in innovative growth concepts?

On January 5th, NUOBIKAN (2635.HK) rebounded from a low level under capital attention. Pharmaceutical growth stocks have been positively influenced by frequent policy benefits, and the market's main line has returned to the growth sector. During the trading session, NUOBIKAN saw a surge in volume, with market sentiment primarily bullish and speculative enthusiasm remaining high. As an innovative newcomer straddling the biomedical and technology services sectors, NUOBIKAN's drug development progress and emerging projects have garnered widespread market attention, with some cutting-edge pipelines entering late-stage trials, and the group's innovative strength closely monitored by external institutions. The intensity of main capital intervention increased during the session, attracting active speculative funds due to its new stock attributes, resulting in significant short-term gains. Technically, this is reflected in a price rebound from a decline, with notable structural rotation characteristics. The MACD shows a bottom divergence and a volume breakout, with the daily structure continuously improving, and the moving average system quickly diverging after a brief convergence. After a high point in the intraday trend, momentum slightly retreated, and the atmosphere of observation and divergence further intensified. The capital realization is manifested by larger intraday fluctuations, and investors need to be cautious of the pullback risks brought by high valuations. Attention should still be paid to sector rotation and fluctuations influenced by news. Under the circumstances of main capital realizing benefits, policy adjustments, or marginal weakening of news, the trend may face pressure and correction. It is recommended to focus on the pharmaceutical growth main line, reasonably control positions, and pay attention to changes in capital trends and industry directions at any time